Product
Help
Pricing
About
Jobs
Log in
Get started
Keyword
Add to collection
OAK trial
Description:
A randomized phase 3 clinical trial comparing atezolizumab with docetaxel in patients with previously treated non-small-cell lung cancer.
Primary topic:
Cancer Immunotherapy and Biomarkers (57%)
Related topics:
Cancer Immunotherapy and Biomarkers (57%),
Lung Cancer Treatments and Mutations (19%)
OpenAlex ID:
keywords/oak-trial
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
2016
·
Achim Rittmeyer
, Fabrice Barlesi
, et al.
·
The Lancet
·
5,056
Efficacy of chemotherapy and atezolizumab in patients with non-small-cell lung cancer receiving antibiotics and proton pump inhibitors: pooled post hoc analyses of the OAK and POPLAR trials
2020
·
M. Chalabi
, A. Cardona
, et al.
·
Annals of Oncology
·
313
Updated Efficacy Analysis Including Secondary Population Results for OAK: A Randomized Phase III Study of Atezolizumab versus Docetaxel in Patients with Previously Treated Advanced Non–Small Cell Lung Cancer
2018
·
Louis Fehrenbacher
, Joachim von Pawel
, et al.
·
Journal of Thoracic Oncology
·
280
Atezolizumab Versus Docetaxel in Pretreated Patients With NSCLC: Final Results From the Randomized Phase 2 POPLAR and Phase 3 OAK Clinical Trials
2020
·
Julien Mazieres
, Achim Rittmeyer
, et al.
·
Journal of Thoracic Oncology
·
207
PDF
Atezolizumab in patients with advanced non-small cell lung cancer and history of asymptomatic, treated brain metastases: Exploratory analyses of the phase III OAK study
2018
·
Shirish M. Gadgeel
, Rimas V. Lukas
, et al.
·
Lung Cancer
·
179
A longitudinal circulating tumor DNA-based model associated with survival in metastatic non-small-cell lung cancer
2023
·
Zoe June F. Assaf
, Wei Zou
, et al.
·
Nature Medicine
·
178
Atezolizumab Treatment Beyond Progression in Advanced NSCLC: Results From the Randomized, Phase III OAK Study
2018
·
David R. Gandara
, Joachim von Pawel
, et al.
·
Journal of Thoracic Oncology
·
169
PDF
Immunotherapy revolutionises non-small-cell lung cancer therapy: Results, perspectives and new challenges
2017
·
Etienne Giroux Leprieur
, Coraline Dumenil
, et al.
·
European Journal of Cancer
·
126
Long-term survival in patients with advanced non–small-cell lung cancer treated with atezolizumab versus docetaxel: Results from the randomised phase III OAK study
2018
·
J. von Pawel
, R. Bordoni
, et al.
·
European Journal of Cancer
·
110
Blood-based biomarkers for cancer immunotherapy: Tumor mutational burden in blood (bTMB) is associated with improved atezolizumab (atezo) efficacy in 2L+ NSCLC (POPLAR and OAK)
2017
·
D.R. Gandara
, M. Kowanetz
, et al.
·
Annals of Oncology
·
97
PDF
Alternative dosing regimens for atezolizumab: an example of model-informed drug development in the postmarketing setting
2019
·
Kari M. Morrissey
, Mathilde Marchand
, et al.
·
Cancer Chemotherapy and Pharmacology
·
95
PDF
Allele Frequency–Adjusted Blood-Based Tumor Mutational Burden as a Predictor of Overall Survival for Patients With NSCLC Treated With PD-(L)1 Inhibitors
2019
·
Zhijie Wang
, Jianchun Duan
, et al.
·
Journal of Thoracic Oncology
·
92
PDF
Primary analysis from OAK, a randomized phase III study comparing atezolizumab with docetaxel in 2L/3L NSCLC
2016
·
F. Barlesi
, K. Park
, et al.
·
Annals of Oncology
·
74
PDF
A Model of Overall Survival Predicts Treatment Outcomes with Atezolizumab versus Chemotherapy in Non–Small Cell Lung Cancer Based on Early Tumor Kinetics
2018
·
Laurent Claret
, Jin Y. Jin
, et al.
·
Clinical Cancer Research
·
73
Racial differences in characteristics and prognoses between Asian and white patients with nonsmall cell lung cancer receiving atezolizumab: An ancillary analysis of the POPLAR and OAK studies
2019
·
Jie Qian
, Wei Nie
, et al.
·
International Journal of Cancer
·
69
PDF
Pre‐ and on‐treatment lactate dehydrogenase as a prognostic and predictive biomarker in advanced non–small cell lung cancer
2022
·
Angelina Tjokrowidjaja
, Sarah J. Lord
, et al.
·
Cancer
·
59
PDF
Development and Validation of a Prognostic Model for Patients with Advanced Lung Cancer Treated with the Immune Checkpoint Inhibitor Atezolizumab
2020
·
Ashley M. Hopkins
, Ganessan Kichenadasse
, et al.
·
Clinical Cancer Research
·
58
ctDNA Predicts Overall Survival in Patients With NSCLC Treated With PD-L1 Blockade or With Chemotherapy
2021
·
Wei Zou
, Stephanie J. Yaung
, et al.
·
JCO Precision Oncology
·
54
PDF
New PD-L1 inhibitors in non-small cell lung cancer – impact of atezolizumab
2017
·
Nagashree Seetharamu
, Isabel Preeshagul
, et al.
·
Lung Cancer Targets and Therapy
·
44
PDF
MA 05.09 Pre-Existing Immunity Measured by Teff Gene Expression in Tumor Tissue is Associated with Atezolizumad Efficacy in NSCLC
2017
·
M. Kowanetz
, W. Zou
, et al.
·
Journal of Thoracic Oncology
·
43
PDF
Abstract 5706: A blood-based next-generation sequencing assay to determine tumor mutational burden (bTMB) is associated with benefit to an anti-PD-L1 inhibitor, atezolizumab
2018
·
David Fabrizio
, Daniel Lieber
, et al.
·
Cancer Research
·
41
A non-linear association between blood tumor mutation burden and prognosis in NSCLC patients receiving atezolizumab
2020
·
Wei Nie
, Jie Qian
, et al.
·
OncoImmunology
·
38
Differential prognostic effect of systemic inflammation in patients with non–small cell lung cancer treated with immunotherapy or chemotherapy: A post hoc analysis of the phase 3 OAK trial
2022
·
Alessio Cortellini
, Biagio Ricciuti
, et al.
·
Cancer
·
36
PDF
Fast progression in patients treated with a checkpoint inhibitor (cpi) vs chemotherapy in OAK, a phase III trial of atezolizumab (atezo) vs docetaxel (doc) in 2L+ NSCLC
2018
·
D.R. Gandara
, M. Reck
, et al.
·
Annals of Oncology
·
36
Integrative evaluation of primary and metastatic lesion spectrum to guide anti-PD-L1 therapy of non-small cell lung cancer: results from two randomized studies
2021
·
Si-Cong Ma
, Xin-Ran Tang
, et al.
·
OncoImmunology
·
34
Show more works
View as search
Works count:
170
Citation count:
8,362
Year
Topic
Type